Q-omics provides the consensus-scored RPS12P23 profile across patient tissues and cancer cell-line models. RPS12P23 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, RPS12P23 is differentially expressed in 7, with the highest sampling consensus in UCEC. Additionally, RPS12P23 RNA expression shows 10,789 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight LUSC, UCEC, and DLBC as cancer lineages where RPS12P23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS12P23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS12P23 survival associations across molecular data types. RPS12P23 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS12P23 RNA expression–survival associations across cancer types. High RPS12P23 expression shows unfavorable associations in KICH, OV, UCEC and CHOL, but favorable associations in LUSC and BLCA. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for RPS12P23 RNA expression.
This table summarizes RPS12P23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS12P23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS12P23 shows lower tumor expression in UCEC and higher tumor expression in COAD, LIHC, STAD, CHOL and THCA. The UCEC box plot shows higher RPS12P23 RNA expression in normal versus tumor tissue (log2 FC = −0.880, t-test p = .010).
This table shows molecular features associated with RPS12P23 in patient tissues and cancer cell lines. In patient samples, RPS12P23 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
